University of Southampton
Southampton Cancer Research UK Centre
Somers Cancer Research Building, MP824
Southampton General Hospital
Developing new cancer treatments
Professor Peter Johnson is the Cancer Research UK's Chief Clinician, and directs the Southampton Cancer Research UK Centre. He is helping to shape the future of our clinical research across the UK. Professor Johnson is a leading expert in lymphoma - a cancer that affects the body's white blood cells. He's also working on new treatments that use the power of the body's own immune system to attack tumours.
Cancer cell survival
When normal cells become damaged, they are either repaired or undergo a process of 'cell suicide' which removes faulty cells from the body. But cancer cells evade this defence mechanism and continue to survive and grow despite extensive damage to their DNA. Together with Professor Graham Packham, Professor Johnson is investigating how lymphoma cells survive.
Their work focuses on a family of proteins that control the balance between cell death and survival in many types of cancer including lymphoma.
Harnessing the immune system to fight cancer
Professor Johnson is at the forefront of immunotherapy research. This exciting approach uses the specificity and power of the body's own immune system to target and destroy cancer cells.
Together with Professor Martin Glennie, Professor Johnson is developing monoclonal antibodies that work by alerting the immune system to the presence of cancer. One of these antibodies, Rituximab, is already in use for the treatment of non-Hodgkin lymphoma. Professor Johnson's team are developing a range of different antibodies some of which are being tested in early-stage clinical trials.
Professor Johnson has been funded by Cancer Research UK for over 15 years. Through his extensive research efforts spanning both basic science and clinical practice, we hope to make many more immunotherapies available to cancer patients in the future.
Other research projects by Peter Johnson
CRUKD/07/063: A Cancer Research UK Phase I trial of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4 given iv weekly for 4 weeks in advanced malignancies refractory to conventional cancer treatment
Funding period: 01 April 2003 to 28 February 2014
CRUK/07/033: RATHL: A randomised trial to assess Response Adapted Therapy using FDG-PET imaging in patients with advanced Hodgkin Lymphoma.
Funding period: 01 May 2008 to 30 April 2015
Funding period: 01 November 2012 to 31 October 2015
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition
Breast Cancer Res Treat.2011;127 :109-119
Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins
Proc Natl Acad Sci U S A.2010;107 :18587-18592